Literature DB >> 33841707

The diagnostic value of miR-145 and miR-205 in patients with cervical cancer.

Furong Yu1, Jie Liu1, Weilei Dong1, Jing Xie1, Xia Zhao1.   

Abstract

OBJECTIVE: To investigate the diagnostic value of miRNA-145 (miR-145) and miRNA-205 (miR-205) in cervical cancer patients.
METHODS: Cervical tissue samples were collected from 144 patients diagnosed with and suspected to have cervical cancer in our hospital. Confirmed by pathology, 84 samples were obtained from cervical cancer patients and 60 samples were from patients with cervical intraepithelial neoplasia. Meanwhile, 30 patients with cervicitis were also selected, and the expression levels of miR-145, miR-205 and human papillomavirus (HPV) were detected in cervical lesions and normal cervical tissue.
RESULTS: In comparison to normal cervical tissue, cervicitis and cervical intraepithelial neoplasia groups, the relative expression level of miR-145 was significantly lower, whereas the relative expression level of miR-205 was notably higher in the cervical cancer group, respectively (P<0.001). The area under the receiver operating characteristic (ROC) curve of miR-145 for diagnosis of cervical cancer in patients was 0.878, of which the sensitivity and the specificity were 0.905 and 0.822, respectively. The area under the ROC curve of miR-205 was 0.881, of which the sensitivity and the specificity was 0.869 and 0.889, respectively. Among all patients, the relative expression level of miR-145 was significantly lower while the relative expression level of miR-205 was considerably higher in HPV-positive patients than those of HPV-negative groups (P<0.001). Parauterine invasion, FIGO stage III-IV and lymphatic metastasis were considered as independent factors that affect the expression of miR-145. FIGO stage III-IV and lymphatic metastasis were independent factors affecting the expression of miR-205.
CONCLUSION: The low expression level of miR-145 and the high expression level of miR-205 in patients with cervical cancer demonstrate a certain diagnostic value in cervical cancer. The expression level of miR-145 and miR-205 is correlated with HPV infection and cervical tumor malignancy. AJTR
Copyright © 2021.

Entities:  

Keywords:  cervical cancer; diagnosis; human papillomavirus infection; miRNA-145; miRNA-205; pathological features

Year:  2021        PMID: 33841707      PMCID: PMC8014394     

Source DB:  PubMed          Journal:  Am J Transl Res        ISSN: 1943-8141            Impact factor:   4.060


  30 in total

1.  Outcomes after minimally invasive surgery in cervical cancer.

Authors:  Talha Khan Burki
Journal:  Lancet Oncol       Date:  2018-11-08       Impact factor: 41.316

2.  MicroRNA-205 regulates ubiquitin specific peptidase 7 protein expression in hepatocellular carcinoma cells.

Authors:  Liang Zhu; Rong Liu; Wei Zhang; Sheng Qian; Jian-Hua Wang
Journal:  Mol Med Rep       Date:  2015-06-25       Impact factor: 2.952

3.  Disease courses in patients with residual tumor following concurrent chemoradiotherapy for locally advanced cervical cancer.

Authors:  Ja Young Kim; Sang Jun Byun; Young Seok Kim; Joo-Hyun Nam
Journal:  Gynecol Oncol       Date:  2016-10-24       Impact factor: 5.482

4.  2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors.

Authors:  Rebecca B Perkins; Richard S Guido; Philip E Castle; David Chelmow; Mark H Einstein; Francisco Garcia; Warner K Huh; Jane J Kim; Anna-Barbara Moscicki; Ritu Nayar; Mona Saraiya; George F Sawaya; Nicolas Wentzensen; Mark Schiffman
Journal:  J Low Genit Tract Dis       Date:  2020-04       Impact factor: 1.925

5.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

6.  Integrin α5 down-regulation by miR-205 suppresses triple negative breast cancer stemness and metastasis by inhibiting the Src/Vav2/Rac1 pathway.

Authors:  Yajuan Xiao; Yunfei Li; Hua Tao; Brock Humphries; Aimin Li; Yiguo Jiang; Chengfeng Yang; Rongcheng Luo; Zhishan Wang
Journal:  Cancer Lett       Date:  2018-06-30       Impact factor: 8.679

7.  miR-34a and miR-125b Expression in HPV Infection and Cervical Cancer Development.

Authors:  Joana Ribeiro; Joana Marinho-Dias; Paula Monteiro; Joana Loureiro; Inês Baldaque; Rui Medeiros; Hugo Sousa
Journal:  Biomed Res Int       Date:  2015-06-09       Impact factor: 3.411

8.  miR-143 and miR-145 disrupt the cervical epithelial barrier through dysregulation of cell adhesion, apoptosis and proliferation.

Authors:  Lauren Anton; Ann DeVine; Luz-Jeannette Sierra; Amy G Brown; Michal A Elovitz
Journal:  Sci Rep       Date:  2017-06-08       Impact factor: 4.379

Review 9.  Human Papillomavirus Infection and Cervical Cancer: Epidemiology, Screening, and Vaccination-Review of Current Perspectives.

Authors:  Chee Kai Chan; Gulzhanat Aimagambetova; Talshyn Ukybassova; Kuralay Kongrtay; Azliyati Azizan
Journal:  J Oncol       Date:  2019-10-10       Impact factor: 4.375

10.  miR-205 regulates the proliferation and invasion of ovarian cancer cells via suppressing PTEN/SMAD4 expression.

Authors:  Ping Chu; Aihua Liang; Aili Jiang; Lu Zong
Journal:  Oncol Lett       Date:  2018-03-21       Impact factor: 2.967

View more
  3 in total

1.  The potential value of microRNA-145 for predicting prognosis in patients with ovarian cancer: A protocol for systematic review and meta-analysis.

Authors:  Zhen Chen; Zelan Xiao; Siheng Zeng; Zhiqiang Yan
Journal:  Medicine (Baltimore)       Date:  2021-08-13       Impact factor: 1.817

2.  Survival‑related DLEU1 is associated with HPV infection status and serves as a biomarker in HPV‑infected cervical cancer.

Authors:  Aiping Dong; Bin Xu; Zhanzhao Wang; Xia Miao
Journal:  Mol Med Rep       Date:  2022-01-11       Impact factor: 2.952

3.  MicroRNA-98-5p modulates cervical cancer progression via controlling PI3K/AKT pathway.

Authors:  RongXin Xiao; Hong Wang; Biao Yang
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.